Evidence map›Paper›PMID 41400104›Full record

ArticleGlia2026

Aberrant Molecular Myelin Architecture in Charcot-Marie-Tooth Disease Type 1A and Hereditary Neuropathy With Liability to Pressure Palsies.

Kathryn R Moss, Marvis A Arowolo, Dave R Gutierrez, Ahmet Höke

Abstract read
In one paragraph

Article in Glia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kathryn R MossDepartment of Physical Medicine and Rehabilitation, University of Missouri School of Medicine, Columbia, Missouri, USA.ORCID 0000-0002-3726-4056
Marvis A ArowoloDepartment of Physical Medicine and Rehabilitation, University of Missouri School of Medicine, Columbia, Missouri, USA.
Dave R GutierrezDepartment of Neurology, Neuromuscular Division, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Ahmet HökeDepartment of Neurology, Neuromuscular Division, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0003-1215-3373

Funding

Function and Regulation of PMP22 in CMT1A and HNPPK22NS125057 · NINDS · UNIVERSITY OF MISSOURI-COLUMBIA · PI MOSS, KATHRYN RENAE · 2021 to 2025
$952k
LSM880 Laser-scanning Microscope with Airyscan ModuleS10OD023548 · OD · JOHNS HOPKINS UNIVERSITY · PI KUO, SCOT CHARLES · 2018 to 2018
$439k
Johns Hopkins University, Merkin Peripheral Neuropathy and Nerve Regeneration CenterNIH HHS S10 OD023548NINDS NIH HHS K22 NS125057NINDS NIH HHS K22NS125057
6 · The paper itself

Abstract

Charcot-Marie-Tooth Disease Type 1A (CMT1A) and Hereditary Neuropathy with Liability to Pressure Palsies (HNPP) are the most common inherited peripheral neuropathies and arise from copy number variation of the Peripheral Myelin Protein 22 (PMP22) gene. While secondary axon degeneration has been proposed as the primary driver of disability, our prior work demonstrated pronounced neuromuscular impairment in CMT1A model mice in the absence of overt axonal loss, prompting investigation into primary myelin dysfunction. Here, we reveal that altered PMP22 dosage profoundly disrupts molecular architecture at critical myelin domains, Schmidt-Lanterman incisures (SLIs) and Nodes of Ranvier. Using high-resolution confocal imaging of teased peripheral nerve fibers from CMT1A and HNPP model mice, we identified widespread disorganization of adherens junctions, mislocalization of Connexin29 and aberrant distribution of nodal ion channels, with several defects more severe in CMT1A, consistent with disease burden. Notably, nodal widening and abnormal spreading of Kv1.2 and Caspr along internodes indicate compromised axo-glial compartmentalization essential for saltatory conduction. Together, these findings support a model in which PMP22 functions as a structural organizer of myelin, coordinating adherens junction patterning and nodal subdomain integrity. Dysregulation of this function is predicted to compromise Schwann-cell architecture, metabolic support and axonal excitability. Our findings support a paradigm shift in which molecular destabilization of myelin, rather than secondary axonal degeneration alone, contributes to disease progression in CMT1A and HNPP. This work also identifies junctional complexes as potential actionable molecular targets and establishes a mechanistic framework applicable to a broad spectrum of inherited dysmyelinating and acquired demyelinating neuropathies.

Indexed as

ArthrogryposisCharcot-Marie-Tooth DiseaseHereditary Sensory and Motor NeuropathyMyelin ProteinsMyelin SheathAnimalsAxonsConnexinsDisease Models, AnimalMaleMiceMice, Inbred C57BLMice, TransgenicRanvier's NodesConnexinsMyelin ProteinsPmp22 protein, mouseCharcot–Marie–Tooth disease (CMT)Charcot–Marie–Tooth disease type 1A (CMT1A)hereditary neuropathy with liability to pressure palsies (HNPP)microscopymyelinneuromuscular diseasenode of Ranvierperipheral myelin protein 22 (PMP22)Schmidt‐Lanterman incisure (SLI)Schwann cell

Identifiers

PMID41400104
PMCPMC12706824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.